T38930 |
BAY-826
|
1448316-08-2
|
98%
|
|
BAY-826 is a novel, potent and selective TIE-2 inhibitor that inhibits TIE-2 phosphorylation and can be used to study tumors.
|
T2054 |
Altiratinib
|
1345847-93-9
|
98%
|
|
Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, c...
|
T4318 |
EOC317
|
939805-30-8
|
98.00%
|
|
EOC317 (ACTB-1003) is an oral kinase inhibitor (IC50: 6/2/4 nM, for FGFR1/VEGFR2/Tie-2).
|
T6129 |
GSK-1070916
|
942918-07-2
|
98.51%
|
|
GSK-1070916 (GSK-1070916A) is a reversible and ATP-competitive inhibitor of Aurora B/C with IC50 of 3.5 nM/6.5 nM. It displays >100-fold selectivity against the ...
|
T14921 |
CE-245677
|
717899-97-3
|
98.99%
|
|
CE-245677 is a potent reversible inhibitor of Tie2 and TrkA/B kinases. With a cellular IC50s of 4.7 and 1 nM.
|
T6934 |
Pexmetinib
|
945614-12-0
|
99.07%
|
|
Pexmetinib (ARRY-614) (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
|
T3113 |
Foretinib
|
849217-64-7
|
99.7%
|
|
Foretinib (GSK1363089) is a broad-spectrum tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR.
|
T79860 |
TIE-2/VEGFR-2 kinase-IN-5
|
1014407-83-0
|
99.79%
|
|
TIE-2/VEGFR-2 kinase-IN-5 is a potent TIE-2 and VEGFR-2 tyrosine kinase receptor inhibitor with anti-angiogenic activity and is commonly used in biomedical resea...
|
T6335 |
Tie2 kinase inhibitor 1
|
948557-43-5
|
99.81%
|
|
Tie2 kinase inhibitor 1 (Tie2 kinase inhibitor), an optimized compound of SB-203580, is selective to Tie2 with IC50 of 0.25 μM, which is 200-fold more effective ...
|